Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Color Diagnostics, |
RCV001526262 | SCV001736570 | uncertain significance | Cardiomyopathy | 2024-03-06 | criteria provided, single submitter | clinical testing | This missense variant replaces isoleucine with leucine at codon 934 of the DSG2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with cardiovascular disorders in the literature. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Mayo Clinic Laboratories, |
RCV002261374 | SCV002541459 | uncertain significance | not provided | 2021-10-13 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004995937 | SCV005575795 | uncertain significance | Cardiovascular phenotype | 2024-10-01 | criteria provided, single submitter | clinical testing | The c.2800A>T (p.I934L) alteration is located in exon 15 (coding exon 15) of the DSG2 gene. This alteration results from a A to T substitution at nucleotide position 2800, causing the isoleucine (I) at amino acid position 934 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |